BHCM
IMNM icon

Brevan Howard Capital Management’s Immunome IMNM Stock Holding History

Brevan Howard Capital Management’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$465K Buy
+21,278
New +$474K ﹤0.01% 1343
2024
Q2 		– Sell
-31,878
Closed -$787K – 1204
2024
Q1 		$787K Buy
+31,878
New +$647K 0.01% 332

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Brevan Howard Capital Management's IMNM Position: Q1 2026 in Review

Brevan Howard Capital Management opened a new position in Immunome (IMNM) in Q1 2026: 21,278 shares worth $465K. The stake represents ﹤0.01% of the portfolio and ranks #1343 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in IMNM as recently as Q1 2024.

Brevan Howard Capital Management first reported a position in IMNM in Q1 2024 and has held it in 2 quarters since. The position peaked at $787K in Q1 2024. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Brevan Howard Capital Management held 21,278 shares of Immunome worth $465K as of Q1 2026.
  • Immunome was a new Brevan Howard Capital Management position in Q1 2026.
  • Immunome made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1343 holding.
  • Brevan Howard Capital Management first reported a position in Immunome in Q1 2024 and has held it in 2 quarters since.
  • Brevan Howard Capital Management's Immunome position peaked at $787K in Q1 2024.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.